News
BioNxt Launches Feasibility Study for Semaglutide Oral Thin Film as Alternative to Injection/Tablets
VANCOUVER, BC / ACCESS Newswire / June 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:BNXTF)(FSE:BXT), is pleased to announce the launch of a feasibility study for the ...
Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing ...
Over the next 12 years through NHS primary care providers, 1.6 million people are expected to receive tirzepatide, a weight ...
Patients who took a lower dose lost more weight on average. Read more at straitstimes.com. Read more at straitstimes.com.
Stocktwits on MSN6h
Novo Nordisk Gains Ground In Obesity Race As Amycretin, Wegovy Show Significant Weight LossNovo Nordisk is likely to draw investor attention on Monday after the company said it is moving forward with the oral and ...
Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that ...
THEY are arguably the biggest medical breakthrough of recent times. And from Monday, so-called ‘fat jabs’ will be made ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback